BPC-157 + TB-500 + GHK-Cu Stack
Three-peptide combination: pentadecapeptide (BPC-157), thymosin beta-4 fragment (TB-500), and copper-binding tripeptide (GHK-Cu)
- Class
- Multi-peptide stack
- Half-life
- Variable
- Route
- Subcutaneous (SubQ)
- Cadence
- Daily
- Evidence
- Weak / anecdotal
Overview
This is a three-peptide stack combining BPC-157, TB-500, and GHK-Cu — three compounds sold separately in the research peptide market and increasingly packaged together as a 'healing' or 'glow' protocol. The pitch is that they hit different stages of tissue repair: BPC-157 for local vascular and gut repair, TB-500 for systemic cell migration and muscle regeneration, and GHK-Cu for collagen remodeling and skin. The stack has become popular in wellness clinics and online peptide communities, often marketed under names like GLOW Stack or extended Wolverine Stack.
The honest assessment: no published study has tested this three-peptide combination in animals or humans. The rationale for stacking them is drawn entirely from their individual mechanisms — BPC-157 promotes angiogenesis and modulates nitric oxide, TB-500 binds actin and supports cell migration, GHK-Cu stimulates collagen synthesis and copper-dependent enzymes. These mechanisms don't obviously conflict, so the idea is that combining them might be additive or synergistic. But 'might' is doing all the work here — there's no controlled evidence that using all three together is better than using one or two, and no data on whether the combination changes safety, dosing, or outcomes.
Each of the three peptides has its own preclinical evidence base (mostly rodent studies, some in vitro work) and its own safety unknowns. BPC-157 has extensive animal data but almost no human trials. TB-500 has a few small human studies (mostly topical wound healing and corneal injury) and is banned by WADA. GHK-Cu has decades of research, mostly in dermatology and wound models. Stacking them means you're multiplying the unknowns — interactions, cumulative angiogenic load, receptor desensitization, and long-term effects are all uncharacterized.
Safety considerations
A few of the safety signals worth knowing — the full list, with dosing context and what to monitor, is inside AIx Core.
- None of these three peptides are FDA-approved for human use. They're sold as research chemicals with no regulatory oversight on purity, sterility, or actual peptide content.
- No published study has tested BPC-157, TB-500, and GHK-Cu together — the combination's safety profile is completely unknown. You're stacking three uncharacterized compounds with overlapping angiogenic and proliferative effects.
- Angiogenesis and cell proliferation are double-edged. All three peptides promote blood vessel growth and tissue remodeling — pathways that could theoretically support tumor growth or metastasis. If you have a history of cancer or undiagnosed masses, using this stack is high-risk guesswork.
+ 3 more safety notes inside AIx Core →
Commonly monitored
Markers and signals people track when researching BPC-157 + TB-500 + GHK-Cu Stack.
- Injection site reactions (redness, swelling, warmth — especially with GHK-Cu due to copper)
- Blood pressure (BPC-157 and TB-500 both affect vascular tone in animal studies)
- Subjective recovery markers (pain, range of motion, wound healing time if applicable)
- Any new lumps, masses, or skin changes (angiogenic peptides + copper can theoretically support tumor growth)
- Complete blood count and liver/kidney function if using long-term (no human safety data for chronic stacking)
Frequently asked questions
What is BPC-157 + TB-500 + GHK-Cu Stack?
Three-peptide combination: pentadecapeptide (BPC-157), thymosin beta-4 fragment (TB-500), and copper-binding tripeptide (GHK-Cu). This is a three-peptide stack combining BPC-157, TB-500, and GHK-Cu — three compounds sold separately in the research peptide market and increasingly packaged together as a 'healing' or 'glow' protocol. The pitch is that they hit different stages of tissue repair: BPC-157 for local vascular and gut repair, TB-500 for systemic cell migration and muscle regeneration, and GHK-Cu for collagen remodeling and skin. The stack has become popular in wellness clinics and online peptide communities, often marketed under names like GLOW Stack or extended Wolverine Stack.
How is BPC-157 + TB-500 + GHK-Cu Stack administered?
Subcutaneous (SubQ), typically daily.
What is the half-life of BPC-157 + TB-500 + GHK-Cu Stack?
Variable — Each peptide has distinct kinetics: BPC-157 ~30 min, TB-500 hours, GHK-Cu minutes to hours.
Is BPC-157 + TB-500 + GHK-Cu Stack approved for human use?
BPC-157 + TB-500 + GHK-Cu Stack is investigational — not approved by the FDA, EMA, or MHRA for human use at the time of writing.
What does the evidence show for BPC-157 + TB-500 + GHK-Cu Stack?
Evidence tier: Weak / anecdotal. No controlled trial has tested BPC-157 + TB-500 + GHK-Cu in combination. The evidence for this stack is entirely inferential — drawn from individual studies of each peptide, not from testing the three together.
What is commonly monitored when researching BPC-157 + TB-500 + GHK-Cu Stack?
Commonly tracked markers + signals: Injection site reactions (redness, swelling, warmth — especially with GHK-Cu due to copper), Blood pressure (BPC-157 and TB-500 both affect vascular tone in animal studies), Subjective recovery markers (pain, range of motion, wound healing time if applicable), Any new lumps, masses, or skin changes (angiogenic peptides + copper can theoretically support tumor growth), Complete blood count and liver/kidney function if using long-term (no human safety data for chronic stacking).
Related compounds
Open this in AIx Core for the full picture
Mechanism breakdown, receptor pathway diagram, full safety list, monitored items, source citations, and one-tap add-to-protocol. Free with any account.